Abstract: Sotuletinib, also known as BLZ945, is a highly selective, brain-penetrant small molecule inhibitor of the colony-stimulating factor 1 receptor (CSF-1R). While primarily investigated in the context of oncology, its profound ability to modulate microglia and macrophages highlights its significant implications for neuroinflammation and the microenvironmental regulation of disease. In models of proneural glioblastoma multiforme (GBM), BLZ945 effectively halts tumor progression and improves survival not by depleting tumor-associated macrophages (TAMs), but by "re-educating" them away from a pro-tumorigenic M2 phenotype. Conversely, in mammary and cervical carcinoma models, BLZ945 attenuates tumor growth by directly depleting regulatory TAMs and enhancing the infiltration of cytotoxic CD8+ T cells. This review synthesizes the pharmacological activity, molecular mechanisms, selectivity profile, and future therapeutic potential of BLZ945 based on recent preclinical studies.
1. Introduction
The microenvironment of various central nervous system (CNS) and peripheral pathologies is heavily influenced by the presence and activation state of macrophages and microglia. Sotuletinib (BLZ945) is a potent, brain-penetrant small molecule inhibitor that specifically targets the colony-stimulating factor 1 receptor (CSF-1R) [1]. CSF-1R signaling is critical for the differentiation, survival, and recruitment of mononuclear phagocytes, including resident brain microglia and tumor-associated macrophages (TAMs) [1][2]. Because macrophage accumulation is often correlated with high disease grade and poor prognosis, targeting the CSF-1/CSF-1R axis has emerged as a compelling therapeutic strategy. BLZ945 has been extensively studied in preclinical models of proneural glioblastoma multiforme (GBM), where it modulates neuroinflammatory responses and stromal cell behavior, as well as in peripheral malignancies such as cervical and mammary carcinomas [1][2].
2. Pharmacological Activity
BLZ945 exhibits robust pharmacological activity across different tissue microenvironments. In the normal brain, administration of BLZ945 leads to a substantial decrease in the number of resident microglia [1]. In transgenic mouse models of proneural GBM (such as the PDGF-B-driven glioma model), BLZ945 treatment halts glioma growth, significantly reduces tumor grade, decreases tumor cell proliferation by 67–98%, and increases apoptosis by 9- to 17-fold [1]. Notably, it significantly improves long-term symptom-free survival in these models [1].
In peripheral tissues, BLZ945 demonstrates potent anti-tumor and immunomodulatory effects. In the mouse mammary tumor virus-driven polyomavirus middle T antigen (MMTV-PyMT) model of breast cancer, BLZ945 decreases primary mammary tumor growth [2]. Similarly, in the keratin 14-expressing human papillomavirus type 16 (K14-HPV-16) transgenic model of cervical carcinogenesis, BLZ945 prevents tumor progression and induces tumor stasis [2]. In these peripheral models, the pharmacological efficacy is characterized by a marked depletion of TAMs and a concurrent increase in the infiltration of CD45+CD3+CD8+ T cells [2].
3. Molecular Mechanism of Action
The primary mechanism of action of BLZ945 is the blockade of CSF-1R kinase activity, which inhibits CSF-1-dependent proliferation and decreases CSF-1R phosphorylation [1]. However, the downstream cellular consequences of this inhibition are highly dependent on the local tissue microenvironment.
In cervical and mammary tumors, BLZ945 disrupts the rapid turnover and recruitment of TAMs. It specifically targets a regulatory subpopulation of TAMs characterized by the expression of IL-10, CD206, and MHCII [2]. By blocking CSF-1R, BLZ945 prevents these macrophages from persisting in the tumor, thereby alleviating immunosuppression and allowing cytotoxic CD8+ T cells to accumulate [2].
Conversely, in the GBM microenvironment, BLZ945 does not deplete TAMs. Glioma cells secrete survival factors—specifically GM-CSF (CSF-2), IFN-γ, and CXCL10—that protect TAMs from BLZ945-induced apoptosis [1]. Instead of dying, the surviving TAMs are "re-educated." BLZ945 treatment downregulates genes associated with the alternatively activated, pro-tumorigenic M2 macrophage phenotype, including arginase 1 (Arg1), mannose receptor C type 1 (Mrc1/CD206), and adrenomedullin (Adm) [1]. Furthermore, CSF-1R inhibition abrogates the heterotypic signaling between macrophages and glioma cells that normally drives tumor proliferation, and it enhances the phagocytic capacity of the macrophages against glioma cells [1].
4. Structure-Activity Relationship (SAR)
While comprehensive structural modifications are not detailed in the provided literature, the structure-activity profile of BLZ945 is defined by its extreme kinase selectivity. BLZ945 possesses a biochemical IC50 for CSF-1R of 1 nM [1]. It is a highly selective compound, exhibiting a greater than 3200-fold higher affinity for CSF-1R compared to other kinases [1]. Importantly, its affinity for the closely related platelet-derived growth factor receptor alpha (PDGFR-α) is approximately 10,000-fold lower than for CSF-1R [1]. This precise selectivity ensures that the therapeutic and biological effects observed in vivo are strictly mediated through CSF-1R inhibition, without confounding off-target inhibition of PDGFR signaling on glioma cells or pericytes [1].
5. Current Limitations
Despite its potent efficacy, BLZ945 therapy faces several limitations. First, macrophage depletion is incomplete and highly tissue-specific. While it successfully depletes normal brain microglia and TAMs in cervical and mammary tumors, it fails to deplete TAMs in GBM due to the protective effects of the tumor microenvironment [1][2]. Second, the effects of BLZ945 on TAM depletion are transient; continuous inhibition of the CSF-1R pathway is essential. In murine models, withdrawal of BLZ945 leads to a complete recovery of TAM populations to baseline levels within just 3 days [2]. Finally, while BLZ945 decreases primary tumor growth in the MMTV-PyMT breast cancer model, it does not significantly affect the density or cumulative burden of pulmonary metastases [2].
6. Future Perspectives
The unique ability of BLZ945 to "re-educate" rather than merely ablate macrophages opens new therapeutic avenues for neuroinflammatory and neuro-oncological diseases. Because myeloid cells can blunt chemotherapeutic responses and promote re-vascularization following irradiation, combining CSF-1R inhibitors like BLZ945 with direct tumor-targeting therapies (e.g., radiation or chemotherapy) holds significant promise for synergistic effects [1]. Furthermore, the identification of a 5-gene "minimal signature" (including Adm, Arg1, F13a1, Mrc1, and Serpinb2) derived from BLZ945-treated TAMs has translational value; this signature accurately predicts a survival advantage in human patients with proneural GBM, independent of total macrophage numbers [1]. Future studies should explore whether other GBM subtypes or neurodegenerative conditions characterized by microglial activation respond similarly to CSF-1R modulation.
